Natalizumab for multiple sclerosis (MS) increases the risk of progressive multifocal leukoencephalopathy (PML).
Objective:
We aimed to assess the effect of natalizumab on cellular composition and functional B cell parameters including patients with natalizumab-associated PML (n=37).
Methods:
Cellular composition by flow cytometry, levels of immunoglobulin (Ig)G/IgM by immunonephelometry, and oligoclonal bands by isoelectric focusing were studied in blood and cerebrospinal fluid.
Results:
In MS patients treated with natalizumab without PML (n=59) the proportion of CD19+ B cells was higher in blood, but lower in cerebrospinal fluid compared with MS patients not treated with natalizumab (n=17). The CD4/CD8-ratio in cerebrospinal fluid was lower, and IgG and IgM levels as well as the IgG index dropped in longitudinal samples during natalizumab therapy. Oligoclonal bands persisted, but the total amount of the intrathecally produced IgG fraction, and the polyclonal intrathecal IgG reactivity to measles, rubella, and zoster declined. At the time of diagnosis of PML patients with natalizumab-associated PML had low total IgG levels in blood and cerebrospinal fluid.
Conclusions:
Natalizumab impacts B and T cell distribution and exerts an inhibitory effect on surrogates of B cell function in periphery and in cerebrospinal fluid, potentially contributing to the increased risk of developing PML.
YednockTACannonCFritzLC. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature1992; 356: 63–66.
2.
del Pilar MartinMCravensPD. Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab. Arch Neurol2008; 65: 1596–1603.
3.
StuveOMarraCMJeromeKR. Immune surveillance in multiple sclerosis patients treated with natalizumab. Ann Neurol2006; 59: 743–747.
4.
WarnkeCMausbergAKStettnerM. Natalizumab affects the T-cell receptor repertoire in patients with multiple sclerosis. Neurology2013; 81: 1400–1408.
5.
ZohrenFToutzarisDKlarnerV. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood2008; 111: 3893–3895.
6.
KrumbholzMMeinlIKumpfelT. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology2008; 71: 1350–1354.
7.
PlanasRJelcicISchipplingS. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol2012; 42: 790–798.
8.
SaureCWarnkeCZohrenF. Natalizumab and impedance of the homing of CD34+ hematopoietic progenitors. Arch Neurol2011; 68: 1428–1431.
9.
JingDOelschlaegelUOrdemannR. CD49d blockade by natalizumab in patients with multiple sclerosis affects steady-state hematopoiesis and mobilizes progenitors with a distinct phenotype and function. Bone Marrow Transplant2010; 45: 1489–1496.
10.
KoopmanGKeehnenRMPalsST. Interaction through the LFA-1/ICAM-1 pathway prevents programmed cell death of germinal center B cells. Adv Exp Med Biol1993; 329: 387–392.
11.
BloomgrenGRichmanSHotermansC. Risk of natalizumab-associated progressive multifocal leukoencephalopathy. N Engl J Med2012; 366: 1870–1880.
12.
WarnkeCMengeTHartungHP. Natalizumab and progressive multifocal leukoencephalopathy: What are the causal factors and can it be avoided?Arch Neurol2010; 67: 923–930.
13.
FineAJSorbelloAKortepeterC. Central nervous system herpes simplex and varicella zoster virus infections in natalizumab-treated patients. Clin Infect Dis2013; 57: 849–852.
14.
WarnkeCRamanujamRPlavinaT. Changes to anti-JCV antibody levels in a Swedish national MS cohort. J Neurol Neurosurg Psychiatry2013; 84: 1199–1205.
15.
SelterRCBiberacherVGrummelV. Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients. Mult Scler2013; 19: 1454–1461.
16.
MancusoRFranciottaDRovarisM. Effects of natalizumab on oligoclonal bands in the cerebrospinal fluid of multiple sclerosis patients: A longitudinal study. Mult Scler2014; In press.
17.
HarrerATumaniHNiendorfS. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler2013; 19: 1209–1212.
18.
WarnkeCvon GeldernGMarkwerthP. The CSF JCV antibody index for diagnosis of natalizumab-associated PML. Ann Neurol2014; In press.
19.
KeirGLuxtonRWThompsonEJ. Isoelectric focusing of cerebrospinal fluid immunoglobulin G: An annotated update. Ann Clin Biochem1990; 27: 436–443.
20.
AnderssonMAlvarez-CermenoJBernardiG. Cerebrospinal fluid in the diagnosis of multiple sclerosis: A consensus report. J Neurol Neurosurg Psychiatry1994; 57: 897–902.
21.
ReiberHPeterJB. Cerebrospinal fluid analysis: Disease-related data patterns and evaluation programs. J Neurol Sci2001; 184: 101–122.
22.
ReiberHUngefehrSJacobiC. The intrathecal, polyspecific and oligoclonal immune response in multiple sclerosis. Mult Scler1998; 4: 111–117.
23.
LeiteRPCarmo-FonsecaMCabecadasJ. Differential expression of cell adhesion molecules in the functional compartments of lymph nodes and tonsils. Clin Mol Pathol1995; 48: M93-M100.
24.
von AndrianUHEngelhardtB. Alpha4 integrins as therapeutic targets in autoimmune disease. N Engl J Med2003; 348: 68–72.
25.
KoopmanGKeehnenRMLindhoutE. Adhesion through the LFA-1 (CD11a/CD18)-ICAM-1 (CD54) and the VLA-4 (CD49d)-VCAM-1 (CD106) pathways prevents apoptosis of germinal center B cells. J Immunol1994; 152: 3760–3767.
26.
SerafiniBRosicarelliBMagliozziR. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol2004; 14: 164–174.
27.
HarrerAWipflerPEinhaeuplM. Natalizumab therapy decreases surface expression of both VLA-heterodimer subunits on peripheral blood mononuclear cells. J Neuroimmunol2011; 234: 148–154.
28.
LindbergRLAchtnichtsLHoffmannF. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol2008; 194: 153–164.
29.
MeiraMSieversCHoffmannF. MiR-126: A novel route for natalizumab action?Mult Scler2014; 20: 1363–1370.
30.
MarshallLJFerenczyMWDaleyEL. Lymphocyte gene expression and JC virus noncoding control region sequences are linked with the risk of progressive multifocal leukoencephalopathy. J Virol2014; 88: 5177–5183.
31.
HouffSABergerJMajorEO. Response to Linberg et al. Natalizumab alters transcriptional expression profiles of blood cell subpopulations of multiple sclerosis patients. J Neuroimmunol2008; 204: 155–156; author reply 157.
32.
WarnkeCSmolianovVDehmelT. CD34+ progenitor cells mobilized by natalizumab are not a relevant reservoir for JC virus. Mult Scler2011; 17: 151–156.
33.
FrohmanEMMonacoMCRemingtonG. JC virus in CD34+ and CD19+ cells in patients with multiple sclerosis treated with natalizumab. JAMA Neurol2014; 71: 596–602.
34.
ChalkiasSDangXBordE. JC virus reactivation during prolonged natalizumab monotherapy for multiple sclerosis. Ann Neurol2014; 75: 925–934.
35.
SkaricaMEcksteinCWhartenbyKA. Novel mechanisms of immune modulation of natalizumab in multiple sclerosis patients. J Neuroimmunol2011; 235: 70–76.
36.
ReidCELiHSurG. Sequencing and analysis of JC virus DNA from natalizumab-treated PML patients. J Infect Dis2011; 204: 237–244.
37.
GorelikLReidCTestaM. Progressive multifocal leukoencephalopathy (PML) development is associated with mutations in JC virus capsid protein VP1 that change its receptor specificity. J Infect Dis2011; 204: 103–114.
38.
BaylissJKarasoulosTMcLeanCA. Frequency and large T (LT) sequence of JC polyomavirus DNA in oligodendrocytes, astrocytes and granular cells in non-PML brain. Brain Pathol2012; 22: 329–336.
39.
SundqvistEBuckDWarnkeC. JC polyomavirus infection is strongly controlled by human leucocyte antigen class II variants. PLoS Pathog2014; 10: e1004084.
40.
PlavinaTCarulliJLiH. B cell-specific signal in whole blood and serum of natalizumab-treated PML patients is revealed using transcript and protein profiling. Neurology2014; 82: Supplement S31.004.
